Amgen AMGN stock has declined 12.6% in the past three months. Investors are increasingly worried about a mix of near-term revenue pressure, patent expirations, obesity-drug competition and uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results